Genetic investigation into the broad health implications of caffeine: evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Genetic investigation into the broad health implications of caffeine : evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization. / Zagkos, Loukas; Cronjé, Héléne T.; Woolf, Benjamin; de La Harpe, Roxane; Burgess, Stephen; Mantzoros, Christos S.; Elliott, Paul; Yuan, Shuai; Larsson, Susanna C.; Tzoulaki, Ioanna; Gill, Dipender.

I: BMC Medicine, Bind 22, Nr. 1, 81, 2024.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Zagkos, L, Cronjé, HT, Woolf, B, de La Harpe, R, Burgess, S, Mantzoros, CS, Elliott, P, Yuan, S, Larsson, SC, Tzoulaki, I & Gill, D 2024, 'Genetic investigation into the broad health implications of caffeine: evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization', BMC Medicine, bind 22, nr. 1, 81. https://doi.org/10.1186/s12916-024-03298-y

APA

Zagkos, L., Cronjé, H. T., Woolf, B., de La Harpe, R., Burgess, S., Mantzoros, C. S., Elliott, P., Yuan, S., Larsson, S. C., Tzoulaki, I., & Gill, D. (2024). Genetic investigation into the broad health implications of caffeine: evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization. BMC Medicine, 22(1), [81]. https://doi.org/10.1186/s12916-024-03298-y

Vancouver

Zagkos L, Cronjé HT, Woolf B, de La Harpe R, Burgess S, Mantzoros CS o.a. Genetic investigation into the broad health implications of caffeine: evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization. BMC Medicine. 2024;22(1). 81. https://doi.org/10.1186/s12916-024-03298-y

Author

Zagkos, Loukas ; Cronjé, Héléne T. ; Woolf, Benjamin ; de La Harpe, Roxane ; Burgess, Stephen ; Mantzoros, Christos S. ; Elliott, Paul ; Yuan, Shuai ; Larsson, Susanna C. ; Tzoulaki, Ioanna ; Gill, Dipender. / Genetic investigation into the broad health implications of caffeine : evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization. I: BMC Medicine. 2024 ; Bind 22, Nr. 1.

Bibtex

@article{637af930b46f437d80b0b4182d9b8f7a,
title = "Genetic investigation into the broad health implications of caffeine: evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization",
abstract = "Background: Caffeine is one of the most utilized drugs in the world, yet its clinical effects are not fully understood. Circulating caffeine levels are influenced by the interplay between consumption behaviour and metabolism. This study aimed to investigate the effects of circulating caffeine levels by considering genetically predicted variation in caffeine metabolism. Methods: Leveraging genetic variants related to caffeine metabolism that affect its circulating levels, we investigated the clinical effects of plasma caffeine in a phenome-wide association study (PheWAS). We validated novel findings using a two-sample Mendelian randomization framework and explored the potential mechanisms underlying these effects in proteome-wide and metabolome-wide Mendelian randomization. Results: Higher levels of genetically predicted circulating caffeine among caffeine consumers were associated with a lower risk of obesity (odds ratio (OR) per standard deviation increase in caffeine = 0.97, 95% confidence interval (CI) CI: 0.95—0.98, p = 2.47 × 10−4), osteoarthrosis (OR = 0.97, 95% CI: 0.96—0.98, P=1.10 × 10−8) and osteoarthritis (OR: 0.97, 95% CI: 0.96 to 0.98, P = 1.09 × 10−6). Approximately one third of the protective effect of plasma caffeine on osteoarthritis risk was estimated to be mediated through lower bodyweight. Proteomic and metabolomic perturbations indicated lower chronic inflammation, improved lipid profiles, and altered protein and glycogen metabolism as potential biological mechanisms underlying these effects. Conclusions: We report novel evidence suggesting that long-term increases in circulating caffeine may reduce bodyweight and the risk of osteoarthrosis and osteoarthritis. We confirm prior genetic evidence of a protective effect of plasma caffeine on risk of overweight and obesity. Further clinical study is warranted to understand the translational relevance of these findings before clinical practice or lifestyle interventions related to caffeine consumption are introduced.",
keywords = "Caffeine, Mendelian randomization, Obesity, Osteoarthritis, Phenome-wide association study",
author = "Loukas Zagkos and Cronj{\'e}, {H{\'e}l{\'e}ne T.} and Benjamin Woolf and {de La Harpe}, Roxane and Stephen Burgess and Mantzoros, {Christos S.} and Paul Elliott and Shuai Yuan and Larsson, {Susanna C.} and Ioanna Tzoulaki and Dipender Gill",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",
year = "2024",
doi = "10.1186/s12916-024-03298-y",
language = "English",
volume = "22",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Genetic investigation into the broad health implications of caffeine

T2 - evidence from phenome-wide, proteome-wide and metabolome-wide Mendelian randomization

AU - Zagkos, Loukas

AU - Cronjé, Héléne T.

AU - Woolf, Benjamin

AU - de La Harpe, Roxane

AU - Burgess, Stephen

AU - Mantzoros, Christos S.

AU - Elliott, Paul

AU - Yuan, Shuai

AU - Larsson, Susanna C.

AU - Tzoulaki, Ioanna

AU - Gill, Dipender

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024

Y1 - 2024

N2 - Background: Caffeine is one of the most utilized drugs in the world, yet its clinical effects are not fully understood. Circulating caffeine levels are influenced by the interplay between consumption behaviour and metabolism. This study aimed to investigate the effects of circulating caffeine levels by considering genetically predicted variation in caffeine metabolism. Methods: Leveraging genetic variants related to caffeine metabolism that affect its circulating levels, we investigated the clinical effects of plasma caffeine in a phenome-wide association study (PheWAS). We validated novel findings using a two-sample Mendelian randomization framework and explored the potential mechanisms underlying these effects in proteome-wide and metabolome-wide Mendelian randomization. Results: Higher levels of genetically predicted circulating caffeine among caffeine consumers were associated with a lower risk of obesity (odds ratio (OR) per standard deviation increase in caffeine = 0.97, 95% confidence interval (CI) CI: 0.95—0.98, p = 2.47 × 10−4), osteoarthrosis (OR = 0.97, 95% CI: 0.96—0.98, P=1.10 × 10−8) and osteoarthritis (OR: 0.97, 95% CI: 0.96 to 0.98, P = 1.09 × 10−6). Approximately one third of the protective effect of plasma caffeine on osteoarthritis risk was estimated to be mediated through lower bodyweight. Proteomic and metabolomic perturbations indicated lower chronic inflammation, improved lipid profiles, and altered protein and glycogen metabolism as potential biological mechanisms underlying these effects. Conclusions: We report novel evidence suggesting that long-term increases in circulating caffeine may reduce bodyweight and the risk of osteoarthrosis and osteoarthritis. We confirm prior genetic evidence of a protective effect of plasma caffeine on risk of overweight and obesity. Further clinical study is warranted to understand the translational relevance of these findings before clinical practice or lifestyle interventions related to caffeine consumption are introduced.

AB - Background: Caffeine is one of the most utilized drugs in the world, yet its clinical effects are not fully understood. Circulating caffeine levels are influenced by the interplay between consumption behaviour and metabolism. This study aimed to investigate the effects of circulating caffeine levels by considering genetically predicted variation in caffeine metabolism. Methods: Leveraging genetic variants related to caffeine metabolism that affect its circulating levels, we investigated the clinical effects of plasma caffeine in a phenome-wide association study (PheWAS). We validated novel findings using a two-sample Mendelian randomization framework and explored the potential mechanisms underlying these effects in proteome-wide and metabolome-wide Mendelian randomization. Results: Higher levels of genetically predicted circulating caffeine among caffeine consumers were associated with a lower risk of obesity (odds ratio (OR) per standard deviation increase in caffeine = 0.97, 95% confidence interval (CI) CI: 0.95—0.98, p = 2.47 × 10−4), osteoarthrosis (OR = 0.97, 95% CI: 0.96—0.98, P=1.10 × 10−8) and osteoarthritis (OR: 0.97, 95% CI: 0.96 to 0.98, P = 1.09 × 10−6). Approximately one third of the protective effect of plasma caffeine on osteoarthritis risk was estimated to be mediated through lower bodyweight. Proteomic and metabolomic perturbations indicated lower chronic inflammation, improved lipid profiles, and altered protein and glycogen metabolism as potential biological mechanisms underlying these effects. Conclusions: We report novel evidence suggesting that long-term increases in circulating caffeine may reduce bodyweight and the risk of osteoarthrosis and osteoarthritis. We confirm prior genetic evidence of a protective effect of plasma caffeine on risk of overweight and obesity. Further clinical study is warranted to understand the translational relevance of these findings before clinical practice or lifestyle interventions related to caffeine consumption are introduced.

KW - Caffeine

KW - Mendelian randomization

KW - Obesity

KW - Osteoarthritis

KW - Phenome-wide association study

U2 - 10.1186/s12916-024-03298-y

DO - 10.1186/s12916-024-03298-y

M3 - Journal article

C2 - 38378567

AN - SCOPUS:85185443899

VL - 22

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 1

M1 - 81

ER -

ID: 389842388